Breaking News, Collaborations & Alliances

I-Mab, Kalbe Genexine Enter Strategic Pact

KG Bio will have option for exclusive rights to commercialize two I-Mab product candidates.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

I-Mab has entered a strategic partnership with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk and Genexine, Inc. KG Bio will receive a right of first negotiation for an exclusive license for the commercialization of two I-Mab discovered product candidates: TJD5, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an I-Mab product candidate to be agreed upon. KG Bio will have a right of first negotiation for exclusive rights to commerc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters